บทความที่มีข้อกำหนดการเข้าถึงสาธารณะ - Andreas Schneeweissดูข้อมูลเพิ่มเติม
ภาพรวมNIHCancer Research UKDFGEuropean CommissionCIHRGovernment of SpainNHMRCHelmholtzMRCNIHRBMBFWellcomeKWFDFFSusan G. KomenFWOA*StarGenome CanadaAcademy of FinlandBreast Cancer Now, UKRCNSwedish Research CouncilDoDYorkshire Cancer Research, UKNMRCNSERCINSERMNWOANRState of CalifoniaGovernment of ItalyAIRC Foundation for Cancer Research in ItalyZonMwNational Research Foundation, SingaporeWorld Cancer Researh Fund, UKSNSFHHMICCSFRQSProstate Cancer UKSCLCPRITHFSP
ไม่มีให้ใช้งานในทุกที่: 15
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results …
P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ...
The lancet oncology 21 (1), 44-59, 2020
ข้อกำหนด: US Department of Defense, US National Institutes of Health
The coming decade in precision oncology: six riddles
A Wahida, L Buschhorn, S Fröhling, PJ Jost, A Schneeweiss, P Lichter, ...
Nature Reviews Cancer 23 (1), 43-54, 2023
ข้อกำหนด: Federal Ministry of Education and Research, Germany
The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer
V Thewes, R Simon, M Hlevnjak, M Schlotter, P Schroeter, K Schmidt, ...
Oncogene 36 (29), 4124-4134, 2017
ข้อกำหนด: Helmholtz Association
Helical tomotherapy as a new treatment technique for whole abdominal irradiation
N Rochet, F Sterzing, A Jensen, J Dinkel, K Herfarth, K Schubert, ...
Strahlentherapie und Onkologie 184 (3), 145, 2008
ข้อกำหนด: German Research Foundation
A plasma metabolite panel as biomarkers for early primary breast cancer detection
B Yuan, S Schafferer, Q Tang, M Scheffler, J Nees, J Heil, S Schott, ...
International journal of cancer 144 (11), 2833-2842, 2019
ข้อกำหนด: Helmholtz Association
Mutational diversity and therapy response in breast cancer: A sequencing analysis in the neoadjuvant GeparSepto trial
S Loibl, D Treue, J Budczies, K Weber, A Stenzinger, WD Schmitt, ...
Clinical Cancer Research 25 (13), 3986-3995, 2019
ข้อกำหนด: Federal Ministry of Education and Research, Germany
Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer
C Peng, M Wallwiener, A Rudolph, K Ćuk, U Eilber, M Celik, C Modugno, ...
International journal of cancer 138 (10), 2499-2509, 2016
ข้อกำหนด: Helmholtz Association
Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study
N Rochet, F Sterzing, AD Jensen, J Dinkel, KK Herfarth, K Schubert, ...
International Journal of Radiation Oncology* Biology* Physics 76 (5), 1382-1389, 2010
ข้อกำหนด: German Research Foundation
Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance
N Pfarr, R Penzel, V Endris, C Lier, C Flechtenmacher, AL Volckmar, ...
Genes, Chromosomes and Cancer 56 (4), 255-265, 2017
ข้อกำหนด: Federal Ministry of Education and Research, Germany
Plasma S100P level as a novel prognostic marker of metastatic breast cancer
C Peng, H Chen, M Wallwiener, C Modugno, K Cuk, D Madhavan, ...
Breast cancer research and treatment 157, 329-338, 2016
ข้อกำหนด: Helmholtz Association
Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer
SF Jauch, S Riethdorf, MR Sprick, F Schütz, B Schönfisch, SY Brucker, ...
Breast Cancer Research and Treatment 173, 155-165, 2019
ข้อกำหนด: Helmholtz Association, European Commission, Federal Ministry of Education …
How the consolidated framework for implementation research can strengthen findings and improve translation of research into practice: a case study
MD Cornelia von Hagens, A Schneeweiss, M Andreas Müller MD, ...
Oncology nursing forum 44 (5), E223, 2017
ข้อกำหนด: Federal Ministry of Education and Research, Germany
Zur prognostischen Relevanz des CTC-Status bei Progress des metastasierten Mammakarzinoms
SF Jauch, S Riethdorf, MR Sprick, F Schütz, B Schönfisch, SY Brucker, ...
Senologie-Zeitschrift für Mammadiagnostik und-therapie 15 (03), 136-137, 2018
ข้อกำหนด: Helmholtz Association, Federal Ministry of Education and Research, Germany
Helical Tomotherapy as a New Treatment Technique for Whole Abdominal Irradiation.
F Sterzing, A Jensen, J Dinkel, K Herfarth, K Schubert, M Eichbaum, ...
Strahlentherapie und Onkologie 184 (3), 2008
ข้อกำหนด: German Research Foundation
Helikale Tomotherapie als neues Therapieverfahren für eine Ganzabdomenbestrahlung
N Rochet, F Sterzing, A Jensen, J Dinkel, K Herfarth, K Schubert, ...
Strahlentherapie und Onkologie 184, 145-149, 2008
ข้อกำหนด: German Research Foundation
มีให้ใช้งานในบางที่: 99
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ...
New England journal of medicine 372 (8), 724-734, 2015
ข้อกำหนด: US National Institutes of Health
Association analysis identifies 65 new breast cancer risk loci
K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ...
Nature 551 (7678), 92-94, 2017
ข้อกำหนด: US National Institutes of Health, Canadian Institutes of Health Research …
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
K Michailidou, P Hall, A Gonzalez-Neira, M Ghoussaini, J Dennis, ...
Nature genetics 45 (4), 353-361, 2013
ข้อกำหนด: US National Institutes of Health, Canadian Institutes of Health Research …
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
I Baccelli, A Schneeweiss, S Riethdorf, A Stenzinger, A Schillert, V Vogel, ...
Nature biotechnology 31 (6), 539-544, 2013
ข้อกำหนด: German Research Foundation
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo …
SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ...
The lancet oncology 14 (6), 461-471, 2013
ข้อกำหนด: US National Institutes of Health
แหล่งที่มาและข้อมูลกองทุนดำเนินการโดยโปรแกรมคอมพิวเตอร์โดยอัตโนมัติ